Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point ...

We recently published a list of Why These 10 Stocks Soared Today. In this article, we are going to take a look at where ...

Adjusted EBITDA improved significantly to $-16.2 million compared to $-43.9 million in Q1 2024, representing a $27.8 million ...

When it comes to shares of Tempus AI (NASDAQ: TEM), many may feel like they're standing on a dock watching the stock sail off ...

Tempus AI shares rose after a Q1 beat, as an analyst highlighted its AI-driven growth, expanding pharma deals, and $1B+ ...

CompanyOverview|NASDAQ:TEM] Tempus AI (NASDAQ: TEM) is an interesting AI story that operates a platform and library for ...

We recently published a list of 12 Most Popular Stocks on Robinhood in 2025. In this article, we are going to take a look at ...

Tempus AI reports first-quarter revenue of $255.74 million, beating estimates of $248.13 million. The AI-focused precision ...

Live Updates Live Coverage Has Ended Tempus AI sentiment heading 3:43 pm by Tempus enters earnings with strong tailwinds but ...

Tempus AI continued to see dramatic revenue and gross profit growth in the first quarter of 2025, with year-over-year revenue ...

Lefkofsky announced a three-year, $200 million data and modeling license agreement with AstraZeneca and Pathos to build the world’s largest foundation model in oncology. This agreement increased ...

We recently published a list of Jim Cramer’s Thoughts on These 13 Stocks. In this article, we are going to take a look at ...